HCC - HEPATOCELLULAR CARCINOMA
Clinical trials for HCC - HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HCC - HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for HCC - HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for liver cancer: triple therapy shows promise
Disease control CompletedThis study tests whether adding a third drug, ipilimumab, to the standard two-drug combination (atezolizumab and bevacizumab) improves survival and tumor shrinkage in people with advanced liver cancer. About 229 patients will receive either the standard two drugs or all three. Th…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Triple therapy boosts survival in tough liver cancer cases
Disease control CompletedThis study tested whether adding a liver-directed chemotherapy infusion (HAIC) to the usual combination of lenvatinib and an immunotherapy drug (PD-1 inhibitor) helps people with advanced liver cancer that has spread into the main blood vessel of the liver. 244 patients with high…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo may reboot treatment for advanced liver cancer
Disease control CompletedThis study looked at 24 patients with advanced liver cancer whose disease got worse after standard treatment with lenvatinib and an immunotherapy drug. Researchers added a third drug, lenalidomide, to see if it could help control the cancer again. The goal was to measure how long…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: Beijing Tsinghua Chang Gung Hospital • Aim: Disease control
Last updated Jun 26, 2026 19:15 UTC